Drug Development

Two NIH biodefense grants to be used for vaccine development

Published in AIDS Weekly, October 27th, 2003

AlphaVax, Inc., has been awarded two U.S. National Institutes of Health (NIH) biodefense grants to develop new vaccines, using the company's proprietary technology, against two groups of disease-causing agents that could be used potentially in terrorist attacks.

The AlphaVax grants total $16.6 million and were made by the National Institute of Allergy and Infectious Disease (NIAID), part of the NIH in Bethesda, Maryland, an agency of the U.S. Department of Health and Human Services.

The first grant for $9.1 million is to develop a vaccine against botulinum neurotoxins, and the second $7.5 million grant is for a vaccine against a group of equine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-10-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry